Binx Health
Creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | $65.0m Valuation: $520m | Series F | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 331 % | (68 %) | (98 %) | 107132 % | 181 % | (56 %) | (100 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (473 %) | (2627 %) | (103191 %) | (61 %) | (69 %) | (295 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (721 %) | (3365 %) | (147141 %) | (140 %) | (17 %) | (364 %) | 3160 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 242 % | 1908 % | 28946 % | 27 % | 4 % | - | - |
Source: Company filings or news article
Related Content
binx health is a healthcare startup that operates in the diagnostic solutions market, providing point-of-care testing services. The company's primary focus is on enhancing community health outcomes by offering high-quality, timely diagnostic solutions that are tailored to the preferred care settings of patients. binx health's services are particularly relevant in today's healthcare landscape, where the way people consume healthcare is rapidly changing.
The company's primary product, binx io, is a molecular point-of-care testing platform. This platform is designed to enable single-visit diagnosis and treatment of chlamydia and gonorrhea infections, two common sexually transmitted diseases. This means that patients can receive a diagnosis and begin treatment in a single visit, improving the efficiency of healthcare delivery and potentially leading to better health outcomes.
binx health's business model is centered on partnering with healthcare providers to expand convenient and equitable access to healthcare. By offering point-of-care diagnostic solutions, binx health helps its partners to overcome traditional barriers to care, extend their reach, and provide exceptional patient experiences. The company generates revenue by selling its diagnostic solutions to these healthcare providers.
In terms of its market, binx health operates in the broader healthcare sector, with a specific focus on diagnostic services. The company's clients are primarily healthcare providers who are looking to improve their diagnostic capabilities and patient care.
Keywords: Healthcare, Diagnostic Solutions, Point-of-Care Testing, binx io, Chlamydia, Gonorrhea, Single-Visit Diagnosis, Healthcare Providers, Patient Care, Diagnostic Services.